Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013:2013:789814.
doi: 10.1155/2013/789814. Epub 2013 Nov 12.

Therapeutic potential of tolerogenic dendritic cells in IBD: from animal models to clinical application

Affiliations
Review

Therapeutic potential of tolerogenic dendritic cells in IBD: from animal models to clinical application

Raquel Cabezón et al. Clin Dev Immunol. 2013.

Abstract

The gut mucosa undergoes continuous antigenic exposure from food antigens, commensal flora derived ligands, and pathogens. This constant stimulation results in controlled inflammatory responses that are effectively suppressed by multiple factors. This tight regulation, necessary to maintain intestinal homeostasis, is affected during inflammatory bowel diseases (IBD) resulting in altered immune responses to harmless microorganisms. Dendritic cells (DCs) are sentinels of immunity, located in peripheral and lymphoid tissues, which are essential for homeostasis of T cell-dependent immune responses. The expression of a particular set of pathogen recognition receptors allows DCs to initiate immune responses. However, in the absence of danger signals, different DC subsets can induce active tolerance by inducing regulatory T cells (Treg), inhibiting inflammatory T helper cell responses, or both. Interestingly, several protocols to generate clinical grade tolerogenic DC (tol-DCs) in vitro have been described, opening the possibility to restore the intestinal homeostasis to bacterial flora by cellular therapy. In this review, we discuss different DC subsets and their role in IBD. Additionally, we will review preclinical studies performed in animal models while describing recent characterization of tol-DCs from Crohn's disease patients for clinical application.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Summary of different mechanisms to induce tolerance by DCs; Treg and Tr1 cells generation, suppression of T effector cells, inhibition of proliferation, apoptosis induction, T cell anergy, and hyporesponsiveness.
Figure 2
Figure 2
General scheme: dendritic cell therapy for Crohn's disease patients. Isolated monocytes are cultured and differentiated into DCs by adding IL-4 and GM-CSF to the media. At day 3, addition of dexamethasone induces the tolerogenic profile, and at day 6, addition of the maturation cytokine cocktail potentiates the tolerogenic properties.

Similar articles

Cited by

References

    1. Hart AL, Al-Hassi HO, Rigby RJ, et al. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology. 2005;129(1):50–65. - PubMed
    1. Coombes JL, Powrie F. Dendritic cells in intestinal immune regulation. Nature Reviews Immunology. 2008;8(6):435–446. - PMC - PubMed
    1. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nature Medicine. 2004;10(5):475–480. - PubMed
    1. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007;449(7161):419–426. - PubMed
    1. Giannoukakis N, Phillips B, Finegold D, Harnaha J, Trucco M. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care. 2011;34(9):2026–2032. - PMC - PubMed

LinkOut - more resources